UY25923A1 - Composición farmacéutica para el tratamiento de diabetes mellitus.- - Google Patents

Composición farmacéutica para el tratamiento de diabetes mellitus.-

Info

Publication number
UY25923A1
UY25923A1 UY25923A UY25923A UY25923A1 UY 25923 A1 UY25923 A1 UY 25923A1 UY 25923 A UY25923 A UY 25923A UY 25923 A UY25923 A UY 25923A UY 25923 A1 UY25923 A1 UY 25923A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical composition
treatment
diabetes mellitus
administration
methyl
Prior art date
Application number
UY25923A
Other languages
English (en)
Inventor
Wolfgang Grell
Andreas Greischel
Gabriele Zahn
Michael Mark
Hansjoerg Knorr
Eckhard Rupprecht
Original Assignee
Boehringer Ingelheim Pharma
Amp
Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36781542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25923(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma, Amp, Co Kg filed Critical Boehringer Ingelheim Pharma
Publication of UY25923A1 publication Critical patent/UY25923A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Una composición farmacéutica para el tratamiento de diabetes mellitus en terapia de largo plazo mediante la cual, al utilizar la dosis simple en lugar de la doble en la administración de la sal o éter del ácido racémico correspondiente, se evita la innecesaria carga alta y de larga duración de sustancias, como resultado de lo cual se obtienen niveles sustancialmente inferiores de sustancia activa en el plasma que van mucho más allá de la ventaja normal de reducir a la mitad la dosis en la administración de enantiómeros que contienen una cantidad eficaz de ácido benzoico de -(S) (+)-2-etoxi-4-[N-[1-(2-piperidino-fenil)-3-metil-1-butil]aminocarbonil-metil] o una sal fisiológicamente aceptable del mismo con ácidos o bases orgánicos o inorgánicos conjuntamente con uno o más vehículos y/o diluyentes inertes.
UY25923A 1991-06-21 2000-01-17 Composición farmacéutica para el tratamiento de diabetes mellitus.- UY25923A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA002111851A CA2111851C (en) 1991-06-21 1991-06-21 (s)(+)-2-ethoxy-4-[n-{1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid
PCT/EP1991/001147 WO1993000337A1 (de) 1991-06-21 1991-06-21 (s)(+)-2-äthoxy-4-[n-[1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]-benzoesäure
SG1996002715A SG43036A1 (en) 1991-06-21 1991-06-21 (S) (+) -2-ethoxy-4-[N-[1-(2-piperidino-phenyl)-3-methyl- 1-buthyl]aminocarbony methyl] - benzoic a cid
CN91104984A CN1048722C (zh) 1991-06-21 1991-07-22 (s)(+)-2-乙氧基-4-[n-[1-(2-哌啶子基-苯基)-3-甲基-1-丁基]氨基羰基甲基]苯甲酸,含该化合物的药物组合物及其制备方法

Publications (1)

Publication Number Publication Date
UY25923A1 true UY25923A1 (es) 2001-08-27

Family

ID=36781542

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25923A UY25923A1 (es) 1991-06-21 2000-01-17 Composición farmacéutica para el tratamiento de diabetes mellitus.-

Country Status (19)

Country Link
EP (1) EP0589874B1 (es)
JP (1) JP2921982B2 (es)
KR (1) KR100496720B1 (es)
CN (1) CN1048722C (es)
AU (1) AU660930B2 (es)
BG (1) BG61690B1 (es)
CA (1) CA2111851C (es)
DE (2) DE10075006I2 (es)
DK (2) DK0589874T3 (es)
FI (1) FI106027B (es)
GR (1) GR3031654T3 (es)
HK (1) HK1011968A1 (es)
NO (2) NO303687B1 (es)
PL (1) PL170210B1 (es)
RO (1) RO113462B1 (es)
SG (1) SG43036A1 (es)
SK (1) SK281246B6 (es)
UY (1) UY25923A1 (es)
WO (1) WO1993000337A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1011673T3 (da) 1997-06-13 2001-07-09 Novo Nordisk As Hidtil ukendt metode til behandling af nidom
IN192862B (es) 1999-11-16 2004-05-22 Ranbaxy Lab Ltd
PE20020617A1 (es) 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US20040102477A1 (en) * 2002-08-23 2004-05-27 Dr. Reddy's Laboratories Limited Polymorphic forms of (S)-Repaglinide and the processes for preparation thereof
US7915421B2 (en) * 2003-05-14 2011-03-29 Cilag Ltd. Method for preparing phenyl acetic acid derivatives
WO2004103983A1 (en) * 2003-05-26 2004-12-02 Biocon Limited Process for the preparation of s(+)-2-ethoxy-4-[n-{1-(2-piperidinophelyl)-3-methyl-1- butyl} aminocarbonylmethyl]benzoic acid derivatives
EP1664008A1 (en) * 2003-08-28 2006-06-07 Ranbaxy Laboratories Limited Process for the preparation of amorphous form of repaglinide
CN1305863C (zh) * 2004-12-27 2007-03-21 浙江大学 (s)-异丙基-(2-哌啶)苯基-甲基胺的合成方法
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
FR2898894B1 (fr) * 2006-03-24 2008-06-06 Genfit Sa Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations
US7763607B2 (en) * 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
WO2008051902A2 (en) * 2006-10-20 2008-05-02 Cpd, Llc Method of restoring the incretin effect
US8101769B2 (en) 2007-02-15 2012-01-24 Actavis Group Ptc Ehf Process for preparing ethyl (S)-2-ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonyl methyl]benzoate and use thereof for the preparation of Repaglinide
WO2009004485A2 (en) * 2007-06-06 2009-01-08 Actavis Group Ptc Ehf Repaglinide substantially free of dimer impurity
EP2019097A1 (en) 2007-07-25 2009-01-28 Aurobindo Pharma Limited Process for preparing (alphaS)-alpha-(2-methylpropyl)-2-(1-piperidinyl)benzenemethanamine
WO2009040818A1 (en) 2007-09-25 2009-04-02 Solubest Ltd Compositions comprising lipophilic active compounds and method for their preparation
DE102008046995B4 (de) * 2008-09-12 2010-08-26 Stada Arzneimittel Ag 2-Ethoxy-benzoesäurederivat
EP2177221A1 (en) 2008-10-20 2010-04-21 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of substantially optically pure Repaglinide and precursors thereof
PE20120403A1 (es) 2009-05-15 2012-05-03 Novartis Ag Aril-piridinas como inhibidoras de sintasa de aldosterona
CA2761853A1 (en) 2009-05-15 2010-11-18 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
AU2010251967B9 (en) 2009-05-28 2014-04-03 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
EA201101672A1 (ru) 2009-05-28 2012-06-29 Новартис Аг Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
CN102712589B (zh) 2009-11-17 2015-05-13 诺华股份有限公司 作为醛固酮合酶抑制剂的芳基-吡啶衍生物
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
JP5575913B2 (ja) 2009-11-30 2014-08-20 ノバルティス アーゲー アルドステロン合成酵素阻害剤としてのイミダゾール誘導体
EP2364977A1 (en) 2010-01-26 2011-09-14 Reuter Chemische Apparatebau KG Process for the enantiomeric enrichment of 3-methyl-1-(2-piperidinophenyl)-1-butylamine
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
CN102267959B (zh) * 2011-07-06 2013-05-01 海南锦瑞制药股份有限公司 一种瑞格列奈晶体、其制备方法及含有该晶体的固体口服制剂
CN103012319B (zh) * 2011-09-20 2015-06-10 浙江九洲药业股份有限公司 瑞格列奈中间体的合成工艺改进
CN102584743A (zh) * 2011-12-28 2012-07-18 中国药科大学 对二甲氨基吡啶瑞格列奈共晶
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
PE20151666A1 (es) 2013-02-14 2015-11-19 Novartis Ag Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
CN105612172A (zh) 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的环状多肽
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
EP3215154B1 (en) 2014-11-07 2020-01-29 Regents of the University of Minnesota Salts and compositions useful for treating disease
BR112017014194A2 (pt) 2015-01-23 2018-01-09 Novartis Ag conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
WO2018034627A1 (en) 2016-08-18 2018-02-22 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Pharmaceutical composition of antidiabetic tablet
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347565A1 (de) * 1983-12-30 1985-07-11 Thomae Gmbh Dr K Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
NO934726D0 (no) 1993-12-20
SG43036A1 (en) 1997-10-17
NO303687B1 (no) 1998-08-17
PL170210B1 (pl) 1996-11-29
FI935724A (fi) 1993-12-20
HK1011968A1 (en) 1999-07-23
KR100496720B1 (ko) 2006-01-27
DE10075006I2 (de) 2004-01-08
EP0589874B1 (de) 1999-09-08
BG98300A (bg) 1994-09-30
RO113462B1 (ro) 1998-07-30
CN1068820A (zh) 1993-02-10
BG61690B1 (bg) 1998-03-31
FI935724A0 (fi) 1993-12-20
JPH06508816A (ja) 1994-10-06
NO934726L (no) 1993-12-20
DK0965591T3 (da) 2002-11-18
FI106027B (fi) 2000-11-15
DE59109151D1 (de) 1999-10-14
CA2111851C (en) 2002-02-26
JP2921982B2 (ja) 1999-07-19
NO1999017I1 (no) 1999-07-20
WO1993000337A1 (de) 1993-01-07
SK281246B6 (sk) 2001-01-18
DE10075006I1 (de) 2000-04-20
CN1048722C (zh) 2000-01-26
EP0589874A1 (de) 1994-04-06
DK0589874T3 (da) 2000-04-03
CA2111851A1 (en) 1993-01-07
SK128093A3 (en) 1994-11-09
GR3031654T3 (en) 2000-02-29
AU8078191A (en) 1993-01-25
AU660930B2 (en) 1995-07-13

Similar Documents

Publication Publication Date Title
UY25923A1 (es) Composición farmacéutica para el tratamiento de diabetes mellitus.-
Hernández et al. Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19
Exner et al. Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial
Demello et al. Comparative study of experimental Clostridium perfringens infection in dogs treated with antibiotics, surgery, and hyperbaric oxygen
CY1114945T1 (el) Φορεας φαρμακου και κιτ φορεα φαρμακου για την αναστολη ινωσης
UY26425A1 (es) Formulación y método antidiabético
EE03292B1 (et) Prootonpumba inhibiitorit sisaldav paljuosaline ravimpreparaat ja selle valmistamise protsess
Donovan et al. Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide
AR004179A1 (es) Sales de (endo,sin)-(-)-3-(3-hidroxi-1-oxo-2-fenilpropoxi)-8-metil-8-(1- metiletil)-8-azoniabiciclo[3.2.1] octano y preparaciones medicamentosasinhalativas que las contienen.
ES2093735T3 (es) Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
DK0490772T3 (da) 1,4-disubstituerede piperaziner, fremgangsmåde til fremstilling heraf og farmaceutiske midler, der indeholder dem
Bertini et al. Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias
AR123570A1 (es) Tratamientos para el edema macular diabético y la agudeza visual disminuida
CO2024002748A2 (es) Profármaco de derivados de pirrolidona como activador de glucocinasa
US3230143A (en) Antihypertensive injection methods using acid addition salts of alkyl esters of alpha-methyl-3, 4-dihy-droxyphenylalanine
KR890004690A (ko) 당뇨병의 치료를 위한 베자피브레이드의 용도
NO912414L (no) Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling.
ES2036560T3 (es) Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension.
Roberts et al. Haemodynamic interactions of high-dose propranolol pretreatment and anaesthesia in the dog III: The effects of haemorrhage during halothane and trichloroethylene anaesthesia
EP2184066A1 (en) Injection, injection solution and injection kit preparation
Arumugam et al. A lethal injection?
ATE247462T1 (de) Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist
Harder et al. Effects of propafenone on TEA-induced action potentials in vascular smooth muscle of canine coronary arteries
ATE2746T1 (de) Piperidinderivate von 4,5-dialkyl-3-hydroxypyrrol-2-carbons[ureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20110408